Overview

The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea

Status:
Active, not recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy (GDMT), who have central sleep apnea (CSA).

Phase:

Phase 3

Details

Lead Sponsor:

Brigham and Women's Hospital

Collaborator:

Ohio State University